Engineered rAAV Capsids for CNS Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated viruses (rAAVs) face challenges in achieving enhanced neurotropic properties for treating central nervous system (CNS) disorders, while minimizing transduction in liver and dorsal root ganglion cells to reduce toxicity.
Innovation Solution
Engineered rAAVs with capsid proteins containing specific amino acid substitutions and peptide insertions are developed to enhance tissue targeting, transduction, and genome integration in CNS and muscle tissues, while reducing biodistribution in liver and dorsal root ganglion cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rAAV vectors are designed to enhance neurotropic properties for treating CNS disorders, then transduction efficiency in CNS tissues is improved, but transduction in liver and dorsal root ganglion cells increases leading to increased toxicity
Solution Approach 1:
The patent applies local quality by engineering specific amino acid substitutions in the AAV capsid protein structure to create distinct binding affinities for different tissue types. The capsid is modified at specific locations (amino acid positions) to enhance affinity for CNS tissue receptors while reducing affinity for liver and dorsal root ganglion cell receptors, thereby achieving tissue-specific transduction patterns.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences in the capsid protein (changing the chemical parameters of the viral surface) to alter tissue tropism. Specific amino acid substitutions change the physical-chemical properties of the capsid, enabling selective binding to CNS tissue while excluding other tissues through modified receptor interactions.
2Productivity
If rAAV vectors are engineered to achieve high transduction in target tissues, then therapeutic efficacy is improved, but off-target transduction increases leading to adverse effects
Solution Approach 1:
The patent applies segmentation by dividing the capsid protein into specific functional domains and modifying individual amino acid positions within these domains. By segmenting the capsid structure and making targeted substitutions at specific positions, the invention achieves selective enhancement of target tissue binding while reducing off-target interactions through localized structural modifications.
3Adaptability or versatility
If conventional AAV capsids are used for gene delivery, then broad tissue distribution is achieved, but specific targeting of CNS and muscle tissues is insufficient
Solution Approach 1:
The patent maintains the overall capsid structure for broad tissue distribution capability while applying local quality modifications at specific amino acid positions to enhance CNS and muscle tissue targeting. The combination of preserved global structure and localized sequence modifications enables both broad adaptability and precise tissue-specific targeting.
Data Source
AI summary
The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences and/or amino acid substitutions that confer and/or enhance desired properties, particularly increased transduction in CNS upon intraparenchymal administration relative to a rAAV having a reference capsid.